San Diego, June 18, 2025 – ProSciento, Inc., a clinical research organization (CRO) focused on metabolic diseases, today announced the appointment of Megan McCormick as Chief Operating Officer (COO). Megan brings nearly three decades of experience in biopharma and clinical research operations, most recently serving as Vice President of Development Operations at PPD, the clinical research subsidiary of Thermo Fisher Scientific.
Over her 28-year career, Megan has led clinical development teams, as well as served in field-based clinical roles, at global organizations including PPD, Eli Lilly, and AstraZeneca. Her expertise spans clinical operations, project delivery, and team development across global trials. At ProSciento, she will oversee operational strategy and execution across all clinical delivery functions, with a focus on scalability, quality, and cross-functional collaboration.
“We are thrilled to welcome Megan to ProSciento,” said Marcus Hompesch, MD, Chairman and CEO of ProSciento. “Her deep operational expertise and track record of leadership across the clinical research landscape make her uniquely suited to help drive our next phase of growth. Megan’s strategic insight and commitment to team development are a strong complement to our mission to deliver scientific and operational excellence metabolic clinical research.”
“I’m honored to join the ProSciento team and support the important work they do and the significant impact they have as the leading clinical research organization focused on metabolic diseases,” said Megan McCormick. “The company’s commitment to quality, innovation, and patient-focused research is inspiring, and I look forward to partnering with the team to advance our capabilities and impact. What excites me most is the opportunity to work alongside such a talented group of professionals who are clearly passionate about what they do.”
About ProSciento
ProSciento is the leading provider of clinical research and patient engagement solutions for metabolic continuum diseases with unparalleled expertise in diabetes, obesity, and steatotic liver disease. As a full-service clinical research organization (CRO), ProSciento works with clients of all sizes worldwide to design and conduct multinational clinical trials, from early clinical development planning through phase III. With two decades as a leading scientific contributor to metabolic continuum research, ProSciento has trusted relationships with clients, partners, and patients, supporting the development of therapeutics and devices that make an important difference in the lives of individuals with metabolic diseases. For more information, please visit www.prosciento.com.